Lipid Nanoparticles Immunogenicity and Toxicity

Kongressthemen
Enhance Your Prediction of PKPD, Accurate Dosing Regime and Immuno-Modulation of LNP for Long-Term Patient Safety and Potency
Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response.

Kongressorganizer (PCO)
Molly Sullivan

Anmerkungen
Brochure: https://go.evvnt.com/1289158-3?pid=4832

Speakers: Vibha Jawa, Executive Director, Bristol Myers Squibb, Tao Niu, Associate Director, Modeling and Simulations, Vertex Pharmaceuticals, and more

https://go.evvnt.com/1289158-2?pid=4832

Frau Molly Sullivan